ACHV Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 10.32%, SMA50 0.63%, SMA200 26.57%). The stock’s 14-day RSI is 56.56 (neutral), while the ATR of 0.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.49% below its high and over 157.07% above its low. Average 10-day trading volume of 2.04 million shares is in line with the 3-month average of 1.87 million, indicating normal recent market interest.

Achieve Life Sciences, Inc. generated EPS of -$1.38 over the past year. Five-year average earnings growth is 50.01%. Wall Street analysts project EPS growth of 46.02% annually over the next five years. The latest quarter delivered EPS of -$0.80. The next quarter is forecast at -$0.29. Next year's EPS is expected at $16.86. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $19.00 to $12.00. The high target offers 169.12% upside. The low target suggests 69.97% downside. The mean target is $13.60. This offers 92.63% upside. Achieve Life Sciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 11, 2026, missed forecasts by 385.2%. The prior quarter beat by -36.67%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 13, 2025.

Achieve Life Sciences, Inc. has 102.90 million shares outstanding. The public float is 74.69 million shares, elevated short interest at 16.07% of float. This equals 16.45 million shares. The short ratio is 12.35 days. Institutional investors hold 64.84% of the float. Insiders own 0.93%. ARMISTICE CAPITAL, LLC holds 843.78 thousand shares, H.I.G. ONCOGENEX, INC. has 545.51 thousand shares and KING THOMAS BRAXTON has 315.14 thousand shares. Over the past six months, insider transactions show net selling. They sold 20.63 thousand shares across 1 transactions.

Achieve Life Sciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.14. This means the shares are trading above this model’s fair value.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) closed at $7.06 USD, losing -$0.22 (-3.02%) from the previous close of $7.28. The stock is currently mid-range between its 52-week high and low $2.62 and $8.64. With a market capitalization of about $724.77 million, Achieve Life Sciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.25). Key stats such as the average daily volume over the past year has been around 1.87 million shares, in line with its 52-week average. Headquartered in Bothell, WA, Achieve Life Sciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Andrew D. Goldberg, the company employs approximately 28 people and listed since October 12, 1995. Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline.

Achieve Life Sciences, Inc. trades at a P/E ratio of -4.55, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -44.98 indicating negative book value, which may reflect financial stress. The P/FCF stands at -15.41, also below market averages.

Our AI price prediction model suggests that Achieve Life Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.68%, with price expected at $7.32 by September 25, 2026, within a range of $6.96 to $7.66 3-Month Outlook: Projected rise of 33.99%, reaching $9.46 by December 10, 2026, with a range of $9.29 to $9.64. 1-Year Outlook: Projected gain of 384.56%, with price at $34.21 by September 10, 2027, within a range of $35.08 to $38.93.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) shares are up 10.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Achieve Life Sciences, Inc. trading at a premium to the broader market with a P/E of -4.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.93, suggesting 111.47% upside. Our AI forecast model points to short-term strength (3.68% over two weeks), a medium-term rise (33.99% over three months), and a longer-term gain (384.56% over one year), with expected trading ranges indicating moderate volatility.